New Enterprise Associates
http://www.nea.com/Home/New Enterprise Associates is a venture capital firm based in Baltimore, MD. The firm has backed more than 160 companies that have gone public and invested in more than 230 companies that have been successfully merged or acquired. NEA focuses its investments in the information technology, healthcare, and energy technology industries. While NEA makes a majority of its investments in the United States, the firm invests around the world in China and India. The firm was founded in 1978.
View Older Stories View More Recent Stories
-
SafeBase Raises $33M in Series B to Accelerate Vision for Friction-Free Security Reviews
-
Merge Expands Footprint in Europe, Facilitating Product Integrations for GDPR-Compliant Companies
-
Form SC 13D/A Korro Bio, Inc. Filed by: New Enterprise Associates 17, L.P.
-
Form 144 Tuya Inc./ADR Filed by: New Enterprise Associates 14, L.P.
-
AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
-
Form SC 13D/A NeueHealth, Inc. Filed by: New Enterprise Associates 15, L.P.
-
Stride Launches Utah's First Independent Worker Portable Benefits Contributions Program
-
NeueHealth Enters into Amendment to its Credit Facility
-
Tony Florence and Mohamad Makhzoumi Named Co-CEOs of NEA; Scott Sandell Assumes Role of Executive Chairman & CIO
-
Timescale Acquires PopSQL to Bring a Modern, Collaborative SQL GUI to PostgreSQL Developers
-
Stride Launches First-Ever Independent Worker Contributions Program for Portable Benefits
-
Form SC 13D/A Adaptimmune Therapeutics Filed by: New Enterprise Associates 14, L.P.
-
SpyGlass Pharma Unveils Compelling 1-Year Data of Its Innovative Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucoma
-
Form SC 13D/A Nkarta, Inc. Filed by: New Enterprise Associates 15, L.P.
-
Kaiser Permanente and Town Hall Ventures launch Habitat Health
-
Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline
-
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
-
HEAVY.AI Introduces HeavyIQ, Delivering Powerful Conversational Analytics Focused on Location and Time Data
-
NEA Appoints Lila Tretikov Partner, Head of AI Strategy
-
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
-
Regulus Therapeutics (RGLS) Enters $100M Oversubscribed Private Placement
-
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
-
Dr. Laura Shawver to be Recognized as 2024 Duane Roth Endowed Award Lecture Recipient at 20th Annual Industry/Academia Precision Oncology Symposium
-
Propense.ai Raises $3M in Seed Funding for AI-Driven B2B Cross-Selling Platform
-
Merge Named to Forbes List of America’s Best Startup Employers 2024 For Second Consecutive Year
-
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
-
Form SC 13D/A GLYCOMIMETICS INC Filed by: NEW ENTERPRISE ASSOCIATES 10 L P
-
FIRE1 Completes Enrollment in U.S. Early Feasibility Study of Innovative Remote Heart Failure Monitoring System
-
CrewLAB Raises $1.6M to Democratize Data & Technology for Endurance Sports Teams
-
Merge Announces its Availability in AWS Marketplace
-
Form SC 13G Sagimet Biosciences Inc. Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
Form SC 13G/A Inozyme Pharma, Inc. Filed by: New Enterprise Associates 15, L.P.
-
Form SC 13G/A Coursera, Inc. Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
Merge Reports Record Customer Growth in 2023 with 60% Increase in New Customer Logos
-
Form SC 13D/A GLYCOMIMETICS INC Filed by: NEW ENTERPRISE ASSOCIATES 10 L P
-
Everside Health and Marathon Health Announce Merger to Meet Accelerating Employer Demand for Advanced Primary Care Services
-
MBX Biosciences Appoints Steven Ryder, M.D., to Board of Directors
-
Form 4 Sagimet Biosciences Inc. For: Jan 29 Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
MBX Biosciences to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
-
Springbig announces changes in its board of directors following the completion of its $8.0 million debt financing with a syndicate of lenders
-
OHAI.AI LAUNCHES AI VIRTUAL ASSISTANT TO REVOLUTIONIZE HOME AND PERSONAL ORGANIZATION IN SUPPORT OF CHIEF HOUSEHOLD OFFICERS
-
ORIC Pharmaceuticals (ORIC) Prices 12.5M Share Offering at $10/sh
-
ORIC Pharmaceuticals Announces $125 Million Private Placement Financing
-
Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia
-
NEA Welcomes Tiffany Luck as Partner on Its Technology Investing Team
-
Sunrise AI Secures Pre-Seed Funding Led by Andrew Ng's AI Fund
-
Boisson Announces Further Expansion of National Wholesale Distribution to Disrupt the $550M Non-Alcoholic Beverage Industry
-
Form SC 13D/A Mirum Pharmaceuticals, Filed by: New Enterprise Associates 16, L.P.
-
ClearMotion to supply smooth suspension tech for Nio's ET9 EV
-
Form SC 13D/A Bright Health Group Inc. Filed by: New Enterprise Associates 15, L.P.

